無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪性肝炎(NASH) の世界市場 (薬剤の種類別、販売チャネル別):機会分析と産業予測 (2021〜2025年)

Non-Alcoholic Steatohepatitis Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025

発行 Allied Market Research 商品コード 310284
出版日 ページ情報 英文 155 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.11円で換算しております。
Back to Top
非アルコール性脂肪性肝炎(NASH) の世界市場 (薬剤の種類別、販売チャネル別):機会分析と産業予測 (2021〜2025年) Non-Alcoholic Steatohepatitis Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025
出版日: 2018年06月01日 ページ情報: 英文 155 Pages
概要

世界のNASH (非アルコール性脂肪性肝炎) 治療薬市場は、2017年には11億7900万米ドル、2025年には214億7800万米ドルと、58.4%のCAGR (複合年間成長率) で成長する見通しです。世界各地でのNASH患者および関連疾患 (糖尿病・肥満症など) の有病者の増加や、革新的なパイプライン製品の治験・上市などが、市場成長の主な要因として挙げられます。

当レポートでは、世界の非アルコール性脂肪性肝炎 (NASH) の市場について調査分析を行い、市場概要、パイプライン分析、薬物クラス、臨床試験、地域別の考察、主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • 主な成功戦略
  • 市場のダイナミクス
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響度の分析
  • パイプライン分析

第4章 NASH (非アルコール性脂肪性肝炎) 市場:薬剤の種類別

  • 概要
    • 市場規模とその予測
  • ビタミンE・ピオグリタゾン
    • 主な市場動向、成長要因、市場機会
    • 市場規模とその予測:地域別
  • オベチコール酸
  • エラフィブラノール (Elafibranor)
  • Selonsertiおよびcenicriviroc

第5章 NALSH市場:販売チャネル別

  • 概要
    • 市場規模とその予測
  • 病院薬局
  • オンライン店舗
  • 小売薬局

第6章 NASH 市場:地域別

  • 概要
    • 市場規模とその予測
  • 北米市場 (米国、カナダ、メキシコ)
    • 主な市場動向、成長要因、市場機会
    • 市場規模とその予測:国別
    • 市場規模とその予測:薬剤の種類別
    • 市場規模とその予測:流通チャネル別
  • 欧州市場 (ドイツ、フランス、英国、イタリア、スペインなど)
  • アジア太平洋地域 (日本、中国、オーストラリア、インド、韓国など)
  • ラテンアメリカ・中東・アフリカ (LAMEA:ブラジル、サウジアラビア、南アフリカなど)

第7章 企業プロファイル

  • Allergan Plc (Tobira Therapeutics Inc.)
    • 企業概要
    • 基本データ
    • 事業内容
    • 製品ポートフォリオ
    • 業績動向
    • 近年の主な戦略展開状況
  • Cadila Healthcare Ltd.
  • Conatus Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gemphire Therapeutics Inc.
  • Genfit SA
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Novartis International AG
  • Shire plc
図表

List of Tables

  • TABLE 01. GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
  • TABLE 02. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR VITAMIN E & PIOGLITAZONE, BY REGION, 2017-2025 ($MILLION)
  • TABLE 03. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR OBETICHOLIC ACID, BY REGION, 2017-2025 ($MILLION)
  • TABLE 04. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR ELAFIBRANOR, BY REGION, 2017-2025 ($MILLION)
  • TABLE 05. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR SELONSERTIB & CENICRIVIROC, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06. GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 07. PHARMACY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR HOSPITAL, BY REGION, 2017-2025 ($MILLION)
  • TABLE 08. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR ONLINE PROVIDERS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 09. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR RETAIL PHARMACY, BY REGION, 2017-2025 ($MILLION)
  • TABLE 10. NONALCOHOLIC STEATOHEPATITIS (NASH) REVENUE, BY REGION, 2017-2025 ($MILLION)
  • TABLE 11. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 12. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
  • TABLE 13. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 14. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 15. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
  • TABLE 16. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 17. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 18. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
  • TABLE 19. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 20. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 21. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
  • TABLE 22. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 23. ALLERGAN: COMPANY SNAPSHOT
  • TABLE 24. ALLERGAN: OPERATING SEGMENTS
  • TABLE 25. ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 26. ZYDUS CADILA: COMPANY SNAPSHOT
  • TABLE 27. ZYDUS CADILA: PRODUCT PORTFOLIO
  • TABLE 28. CONATUS: COMPANY SNAPSHOT
  • TABLE 29. CONATUS: PRODUCT PORTFOLIO
  • TABLE 30. GALMED: COMPANY SNAPSHOT
  • TABLE 31. GALMED: PRODUCT PORTFOLIO
  • TABLE 32. GEMPHIRE: COMPANY SNAPSHOT
  • TABLE 33. GEMPHIRE: PRODUCT PORTFOLIO
  • TABLE 34. GENFIT: COMPANY SNAPSHOT
  • TABLE 35. GENFIT: PRODUCT PORTFOLIO
  • TABLE 36. GILEAD: COMPANY SNAPSHOT
  • TABLE 37. GILEAD: PRODUCT PORTFOLIO
  • TABLE 38. INTERCEPT: COMPANY SNAPSHOT
  • TABLE 39. INTERCEPT: PRODUCT PORTFOLIO
  • TABLE 40. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 41. NOVARTIS: OPERATING SEGMENTS
  • TABLE 42. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 43. SHIRE: COMPANY SNAPSHOT
  • TABLE 44. SHIRE: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP PLAYER POSITIONING
  • FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 20142018*
  • FIGURE 05. TOP WINNING STRATEGIES, BY DEVELOPMENT, 20142018* (%)
  • FIGURE 06. TOP WINNING STRATEGIES, BY COMPANY, 20142018*
  • FIGURE 07. IMPACT ANALYSES
  • FIGURE 08. NONALCOHOLIC STEATOHEPATITIS (NASH) PIPELINE (POTENTIAL PHASE II AND III DRUGS)
  • FIGURE 09. U.S. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 10. CANADA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 11. MEXICO NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 12. GERMANY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 13. FRANCE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 14. UK NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 15. ITALY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 16. SPAIN NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 17. REST OF EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 18. JAPAN NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 19. CHINA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 20. AUSTRALIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 21. INDIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 22. SOUTH KOREA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 23. REST OF ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 24. BRAZIL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 25. SAUDI ARABIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 26. SOUTH AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 27. REST OF LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2025 ($MILLION)
  • FIGURE 28. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 29. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 30. ZYDUS CADILA: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 31. ZYDUS CADILA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 32. CONATUS: NET SALES, 20162017 ($MILLION)
  • FIGURE 33. GALMED: NET SALES, 20162017 ($MILLION)
  • FIGURE 34. GENFIT: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 35. GILEAD: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 36. GILEAD: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 37. INTERCEPT: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 38. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 39. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 40. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 41. SHIRE: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 42. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
  • FIGURE 43. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
目次
Product Code: LI_14224

The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.

The nonalcoholic steatohepatitis (NASH) market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.

The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type

  • Vitamin E & Pioglitazone
  • Obeticholic Acid (OCA)
  • Elafibranor
  • Selonsertib & Cenicriviroc

By Sales Channel

  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Allergan plc. (Tobira Therapeutics)
  • Cadila Healthcare Limited
  • Conatus Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd
  • Gemphire Therapeutics Inc.
  • Genfit SA
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Novartis International AG
  • Shire Plc.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
    • 2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets, 2021
    • 3.2.2. Top player positioning
  • 3.3. Top winning strategies
  • 3.4. MARKET DYNAMICS
    • 3.4.1. Drivers
      • 3.4.1.1. Upsurge in NASH-affected population
      • 3.4.1.2. Rise in prevalence of diabetes & obesity
      • 3.4.1.3. Surge in healthcare expenditures worldwide
    • 3.4.2. Restraints
      • 3.4.2.1. Insufficient diagnostic technologies for NASH
      • 3.4.2.2. Poor demand in the underdeveloped countries
    • 3.4.3. Opportunities
      • 3.4.3.1. Strong presence of pipeline drugs
      • 3.4.3.2. Unmet needs for NASH therapeutics
      • 3.4.3.3. Growth opportunities in the emerging markets
    • 3.4.4. Impact analyses
  • 3.5. Pipeline analyses

CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Vitamin E & pioglitazone
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
  • 4.3. Obeticholic acid
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
  • 4.4. Elafibranor
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
  • 4.5. Selonsertib & cenicriviroc
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region

CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital pharmacy
    • 5.2.1. Market size and forecast, by region
  • 5.3. Online providers
    • 5.3.1. Market size and forecast, by region
  • 5.4. Retail pharmacy
    • 5.4.1. Market size and forecast, by region

CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. Market size and forecast, by country
      • 6.2.2.1. U.S. market size and forecast
      • 6.2.2.2. Canada market size and forecast
      • 6.2.2.3. Mexico market size and forecast
    • 6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
    • 6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Market size and forecast, by country
      • 6.3.2.1. Germany market size and forecast
      • 6.3.2.2. France market size and forecast
      • 6.3.2.3. UK market size and forecast
      • 6.3.2.4. Italy market size and forecast
      • 6.3.2.5. Spain market size and forecast
      • 6.3.2.6. Rest of Europe market size and forecast
    • 6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
    • 6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Market size and forecast, by country
      • 6.4.2.1. Japan market size and forecast
      • 6.4.2.2. China market size and forecast
      • 6.4.2.3. Australia market size and forecast
      • 6.4.2.4. India market size and forecast
      • 6.4.2.5. South Korea market size and forecast
      • 6.4.2.6. Rest of Asia-Pacific market size and forecast
    • 6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
    • 6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. Market size and forecast, by country
      • 6.5.2.1. Brazil market size and forecast
      • 6.5.2.2. Saudi Arabia market size and forecast
      • 6.5.2.3. South Africa market size and forecast
      • 6.5.2.4. Rest of LAMEA market size and forecast
    • 6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
    • 6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel

CHAPTER 7: COMPANY PROFILES

  • 7.1. Allergan Plc (Tobira Therapeutics Inc.)
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. Cadila Healthcare Ltd.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Product portfolio
    • 7.2.4. Business performance
  • 7.3. Conatus Pharmaceuticals, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
    • 7.3.6. Key strategic moves and developments
  • 7.4. Galmed Pharmaceuticals Ltd.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. Gemphire Therapeutics Inc.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Key strategic moves and developments
  • 7.6. Genfit SA
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. Gilead Sciences, Inc.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. Intercept Pharmaceuticals, Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. Novartis International AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product portfolio
    • 7.9.5. Business performance
    • 7.9.6. Key strategic moves and developments
  • 7.10. Shire plc
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments
Back to Top